^
    Back
    Association details:
    Biomarker:MYC amplification
    Cancer:Small Cell Lung Cancer
    Drug:prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib

    Published date:
    07/15/2017
    Excerpt:
    Proteomic analysis identified CHK1 and MYC as top predictive biomarkers of LY2606368 sensitivity, suggesting that CHK1 inhibition may be especially effective in SCLC with MYC amplification or MYC protein overexpression.
    DOI:
    10.1158/0008-5472.CAN-16-3409